Skip to Main Content


Skip Nav Destination


In This Issue

In the Spotlight

In Focus


Research Briefs

Sotorasib and other selected KRASG12C inhibitors leverage differential dependence on switch-II pocket binding at amino acid position 95 to target all RASG12C isoforms, which has critical implications for the treatment of NRASG12C- or HRASG12C-mutant tumors.

A dual-recombinase reversible knock-in/knock-out mouse model of Jak2V617F validates the absolute requirement of Jak2V617F in sustaining myeloproliferative neoplasms and provides rationale for the clinical development of mutant-selective JAK2V617F inhibitors.

Preventing the feedback induction of TREX1 downstream of tumor cell STING results in robust interferon signaling and can render cancer cells vulnerable to NK and other immune cell–mediated killing, as well as immune checkpoint blockade.

Research Articles

A phase II sequential chemoimmunotherapy trial in frontline stomach cancer demonstrates the importance of early tumor microenvironment remodeling to inform patients who benefit from adding the anti–PD-1 inhibitor pembrolizumab.

A multi-cohort, pan-cancer analysis uncovered racial disparities in cancer genomes between Asian and White populations and elucidated pairwise relationships of driver alterations, providing valuable resources for precision medicine in cancer.

A large panel of patient-derived xenograft models of small cell lung cancer reveal that extrachromosomal amplifications of MYC family genes arise after relapse to drive cross-resistance to multiple chemotherapeutic regimens.

Patient-derived xenografts from pre- and post-treatment biopsies reflect the antitumor activity seen with HER2 antibody zanidatamab in a clinical trial and highlight MET amplification as a mechanism of acquired resistance.

A screen of 109 anticancer drugs in 755 pan-cancer cell lines, accompanied by a prioritization framework, was conducted, and three examples of high-priority hits that offered a combination benefit were described and confirmed both in vitro and in vivo.

Epigenetic reprogramming underlies dormancy after endocrine treatment in estrogen receptor–positive breast cancer, and targeting the epigenome during this adaptation has potential clinical implications.


Close Modal

or Create an Account

Close Modal
Close Modal